Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
Sponsor: MAXVAX Biotechnology Limited Liability Company
Summary
The purpose of this study is to assess the immunogenicity, safety and immune persistence of recombinant trivalent rotavirus subunit vaccine in healthy infants aged 6-12 weeks and healthy toddlers aged 7-71 months.
Official title: A Phase II Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Subunit Rotavirus Vaccine in Healthy Infants Aged 6-12 Weeks and Healthy Toddlers Aged 7-71 Months
Key Details
Gender
All
Age Range
6 Weeks - 71 Months
Study Type
INTERVENTIONAL
Enrollment
1512
Start Date
2023-01-08
Completion Date
2024-12
Last Updated
2024-11-20
Healthy Volunteers
Yes
Interventions
Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
High dose Recombinant Trivalent Subunit Rotavirus Vaccine
0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
Placebo
0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.
Locations (2)
Shangqiu Liangyuan District Center for Disease Control and Prevention
Shangqiu, Henan, China
Ningling County Center for Disease Control and Prevention
Shangqiu, Henan, China